Genprex Ownership
| GNPX Stock | USD 1.14 0.04 3.64% |
Shares in Circulation | First Issued 2016-03-31 | Previous Quarter 2.2 M | Current Value 3.5 M | Avarage Shares Outstanding 20.6 M | Quarterly Volatility 16.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Genprex |
Genprex Stock Ownership Analysis
The company recorded a loss per share of 10.69. Genprex had not issued any dividends in recent years. The entity had 1:40 split on the 2nd of February 2024. Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas. Genprex operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people. To learn more about Genprex call Ryan MS at 877-774-4679 or check out https://www.genprex.com.Besides selling stocks to institutional investors, Genprex also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Genprex's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Genprex's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Genprex Quarterly Liabilities And Stockholders Equity |
|
About 6.0% of Genprex are currently held by insiders. Unlike Genprex's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Genprex's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Genprex's insider trades
Genprex Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Genprex is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Genprex backward and forwards among themselves. Genprex's institutional investor refers to the entity that pools money to purchase Genprex's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Royal Bank Of Canada | 2024-06-30 | 63.0 | Vitalstone Financial Llc | 2024-09-30 | 10.0 | Global Retirement Partners, Llc. | 2024-09-30 | 5.0 | Jpmorgan Chase & Co | 2024-06-30 | 5.0 | Signaturefd, Llc | 2024-06-30 | 0.0 | Brown Brothers Harriman & Co | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Financial Gravity Wealth, Inc. | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 218 K | Geode Capital Management, Llc | 2024-06-30 | 16.5 K |
Genprex Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Genprex insiders, such as employees or executives, is commonly permitted as long as it does not rely on Genprex's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Genprex insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pearson Robert W. over three months ago Disposition of 161396 shares by Pearson Robert W. of Genprex at 0.96 subject to Rule 16b-3 | ||
Genprex, Inc. over three months ago Acquisition by Genprex, Inc. of 551284 shares of Genprex at 2.15 subject to Rule 16b-3 | ||
John Varner over six months ago Payment of 2642 shares by John Varner of Genprex subject to Rule 16b-3 | ||
Ryan Confer over six months ago Disposition of 1126 shares by Ryan Confer of Genprex at 4.4 subject to Rule 16b-3 | ||
John Varner over a year ago Genprex exotic insider transaction detected | ||
Longnecker Brent M over a year ago Acquisition by Longnecker Brent M of 123795 shares of Genprex subject to Rule 16b-3 | ||
Vaczy Catherine M over a year ago Purchase by Vaczy Catherine M of 20000 shares of Genprex | ||
Ryan Confer over a year ago Acquisition by Ryan Confer of 245000 shares of Genprex subject to Rule 16b-3 |
Genprex Outstanding Bonds
Genprex issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Genprex uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Genprex bonds can be classified according to their maturity, which is the date when Genprex has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| Genworth Financial 65 Corp BondUS37247DAB29 | View | |
| Genworth Financial 7629 Corp BondUS37247DAG16 | View | |
| US372460AA38 Corp BondUS372460AA38 | View | |
| GPC 175 01 FEB 25 Corp BondUS372460AB11 | View | |
| GPC 275 01 FEB 32 Corp BondUS372460AC93 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Genprex Stock Analysis
When running Genprex's price analysis, check to measure Genprex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genprex is operating at the current time. Most of Genprex's value examination focuses on studying past and present price action to predict the probability of Genprex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genprex's price. Additionally, you may evaluate how the addition of Genprex to your portfolios can decrease your overall portfolio volatility.